- AdventHealth
ORLANDO, Fla. — Venezuela holds a special place in Dr. José Alexander’s heart. It was there that he spent his childhood, making memories and enjoying the best food with his family, including his aunt Cruz. It’s also where he earned his medical degree at the Central University of Venezuela, an important milestone on his path to becoming a microbiologist.
Alexander, who serves as medical director of the microbiology and virology department for AdventHealth’s Central Florida Division — South Region, moved to the United States in 2010 and joined AdventHealth in 2016.
At AdventHealth, Alexander and his team researched and developed a new test for brain-eating amoeba that produces results within three hours. “The groundbreaking brain-eating amoeba test has changed the landscape for rapid and appropriate treatment for this severe and usually deadly infection,” said Alexander.
The free-living parasite Naegleria fowleri, also known as brain-eating amoeba, is a growing health concern across the U.S. It kills more than 97% of people infected due to delays in identifying and treating the illness.
For the past year, physicians at AdventHealth have been able to receive results in a few hours, rapidly ruling out the presence of the amoeba in patient samples. In addition, physicians in other states can get results in roughly 24 hours from specimens sent to the Orlando campus.
“In the last couple of months, we have tested sample transportation temperatures to determine sample stability,” said Alexander. “This research has led to findings that now allows spinal fluid samples to be shipped from any hospital across the U.S. at room temperature, simplifying the transportation process, extending the viable testing window, and ultimately accelerating diagnosis to potentially save lives.”
A leading innovator in the field, Alexander and his team at AdventHealth Orlando are currently leading an effort to implement next-generation sequencing (NGS) technology in order to identify mycobacteria (such as TB) infections more quickly and accurately, allowing for more precise treatments to begin much sooner.
In his spare time, Alexander enjoys traveling, playing bass and photography. In celebrating Hispanic Heritage Month, he said it’s essential to be a role model for the next generation and lead by example.
“One of the most rewarding aspects of my job is knowing that every discovery or new clinical advancement we make can improve people's lives,” he said. “I hope to inspire the next generation of scientists and I’m excited for what’s to come.”
Alexander is committed to sharing his knowledge and discoveries with colleagues here in the United States, in his native Venezuela and in other South American countries.
“As a Venezuelan, I believe that one of the most important aspects of our culture is our capacity to maintain a positive attitude by helping each other, whether through food, stories, or music, even when times are hard.”
Recent News
AdventHealth Cancer Institute Advances the Use of CAR T-Cell Therapy for Multiple Myeloma
CAR-T therapies have emerged as new treatment options for certain types of cancer through a one-time infusion that can lead to long-lasting remission.
AdventHealth Graduate Medical Education Program Celebrates 50 Years
Growing from a family practice residency to 24 accredited programs, AdventHealth’s Graduate Medical Education (GME) program celebrates 50 years.
New Clinical Trial Explores Digital Intervention for Apathy in Late-life Depression
Afflicting 30-50% of patients with late-life depression, apathy is a challenging psychiatric syndrome in older adulthood that can result in lack of motivation leading to poor self-care, physical...
AdventHealth Performs Central Florida’s First Liver Transplant for Unresectable Colorectal Liver Metastases
In June 2025, AdventHealth Abdominal Transplant Surgeon and Surgical Oncologist Ryan Day, MD, worked with a multidisciplinary team to perform Central Florida’s first liver transplant for unresectable...
AdventHealth Neuroscience Institute First in Florida to be Recognized as a GammaTile Center of Excellence
GammaTile is the first and only tile-based radiation therapy for the treatment of
operable brain tumors. The AdventHealth Neuroscience Institute began performing GammaTile procedures in 2021 and was...
An AdventHealth Collaboration Explores the Impact of Microgravity and Electrical Stimulation on Muscle Cell Health in Space
Using a muscle lab-on-chip model aboard the International Space Station (ISS), AdventHealth Translational Research Institute’s Dr. Paul Coen has been working with a multidisciplinary team from the...
AdventHealth Neuroscience Institute Among First in U.S. to Offer Phase IIa Clinical Trial of Troculeucel for Moderate Alzheimer’s Disease
While most clinical trials for Alzheimer’s disease have focused on patients with early or mild cognitive impairment, roughly 30% of those with Alzheimer’s have moderate stage disease for which there...
AdventHealth Translational Research Institute Selected as Clinical Site for National Study of Muscle, Mobility and Aging (SOMMA)
Under the leadership of Scientific Director and Principal Investigator Bret H. Goodpaster, PhD, the AdventHealth Translational Research Institute (TRI) is now enrolling men and women 70 years of age...
AdventHealth Neuroscience Institute Administers First Dose of Investigative NK Cell Therapy to Person with Alzheimer’s Disease
Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...
New Study Published in the New England Journal of Medicine Shows the Addition of Regional Nodal Irradiation Does Not Decrease Rate of Invasive Breast Cancer Recurrence in Patients with Negative Axillary Nodes Following Neoadjuvant Chemotherapy
Findings of the phase III, multicenter, randomized NSABP B-51-RTOG 1304 clinical trial were recently published in the New England Journal of Medicine with AdventHealth Cancer Institute’s Dr. Mamounas...
AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease
Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...
AdventHealth Research Institute Offers Phase II Clinical Trial of Etanercept for Treatment of Blast-Induced Tinnitus
Approximately 1 billion people throughout the world suffer from tinnitus (ringing in the ears), and it is the number one disability of those who serve in the U.S. military. The condition can disrupt...